CureVac (NASDAQ:CVAC - Get Free Report)'s stock price was up 4.7% during mid-day trading on Thursday . The stock traded as high as $2.88 and last traded at $2.88. Approximately 363,333 shares were traded during mid-day trading, a decline of 56% from the average daily volume of 816,999 shares. The stock had previously closed at $2.75.
Analyst Ratings Changes
Separately, JMP Securities reiterated a "market outperform" rating and set a $16.00 target price on shares of CureVac in a research note on Monday, September 16th.
Check Out Our Latest Report on CVAC
CureVac Price Performance
The company's 50-day moving average price is $2.84 and its two-hundred day moving average price is $3.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The company has a market capitalization of $669.40 million, a P/E ratio of 5.44, a price-to-earnings-growth ratio of 0.24 and a beta of 2.59.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. bought a new stake in shares of CureVac during the second quarter worth approximately $8,237,000. Jane Street Group LLC lifted its holdings in CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock worth $235,000 after purchasing an additional 55,867 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in CureVac by 99.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company's stock worth $147,000 after purchasing an additional 21,999 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in CureVac by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company's stock valued at $127,000 after purchasing an additional 16,792 shares during the period. Finally, XTX Topco Ltd acquired a new position in CureVac in the 2nd quarter valued at $108,000. Institutional investors and hedge funds own 17.26% of the company's stock.
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Recommended Stories
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
